Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the health-check domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /nas/content/live/brownpelican/wp-includes/functions.php on line 6121

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the mfn-opts domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /nas/content/live/brownpelican/wp-includes/functions.php on line 6121
Louisiana AG Faces FDA and Abortion Pill Manufacturers in Court, by Carole Novielli – Brown Pelican Society of Lousiana

Louisiana AG Faces FDA and Abortion Pill Manufacturers in Court, by Carole Novielli

Pro-Abortion Professor Backs Off Leadership Appointment at Notre Dame After Backlash by Daniel Payne

February 27, 2026

Meet the New Campus Radicals, by Andrea M. Picciotti-Bayer

February 27, 2026

An image by Grok. The state of Louisiana with an image Mifepristone being banned.

By Carole Novielli, Live Action News, Feb 26, 2026

The State of Louisiana faced off against the Food and Drug Administration (FDA) in a US District Court this week over mail-order access to the abortion pill. The State is seeking a preliminary injunction against the FDA’s 2023 REMS safety protocol changes, which included the removal of in-person dispensing requirements for the abortion pill mifepristone (200mg).

Key Takeaways:

Louisiana is seeking an injunction on the 2023 REMS safety rule changes that allowed the abortion pill mifepristone to be dispensed through the mail and sold in pharmacies.
The State argues that allowing the abortion pill to be dispensed via the mail violates the Comstock Act, causes sovereign harm by facilitating illegal abortions, and causes economic harm by increasing Louisiana’s Medicaid costs.
The FDA claimed that Louisiana’s lawsuit will “short circuit” its ongoing review of mifepristone.
The judge did not indicate when he would issue his ruling, but did give FDA attorneys seven days to file a brief on what emergency action it would take if it found mifepristone to be a public health risk. ….

Continue reading >>>>>>>>>